

SUPPLEMENTS

OJO, A., ZHANG, S., BLEIBDREY , N., ZIMSKIND , D., KESHVANI , N., & CHALMERS , R. Persistence and switching patterns of migraine prophylactic medications in Canada: a retrospective claims analysis comparing adherence and evaluating the economic burden of illness . J PHARM PHAR SCI. 2022, 25, 402–417. <https://doi.org/10.18433/JPPS33158>




Figure S1 – Kaplan-Meier survival analysis of patient retention on each drug class over 365 days

Table T1 – 1 year patient retention and confidence intervals from Kaplan-Meier survival analysis

Drug Class	1 year retention	90% CI
Angiotensin Receptor Blockers	0.647	(0.581 – 0.714)
CGRP Receptor mAb	0.526	(0.338 – 0.715)
Serotonin Antagonists	0.333	(0.0168 – 0.650)
Beta Blockers	0.324	(0.280 – 0.368)
Antidepressants	0.320	(0.0294 -0.346)
Neurotoxin	0.306	(0.237 – 0.375)
Anticonvulsants	0.259	(0.227 – 0.292)
Calcium Channel Blockers	0.254	(0.164 – 0.344)
ACE Inhibitors	0.167	(0.000 - 0.417)

Table T2 – Medication Definitions

Drug Categories	Compounds
Triptan	Almotriptan (Axert) Eletriptan (Relpax) Frovatriptan (Frova) Lasmiditan (Reyvow) Naratriptan (Amerge) Rizatriptan (Maxalt) Sumatriptan (Imitrex, Onzetra Xsail, Sumavel DosePro, Zembrace) Zolmitriptan (Zomig)
Migraine prophylactic	Propranolol Metoprolol Nadolol Amitriptyline Nortriptyline Topiramate Candesartan Gabapentin Divalproex Pizotifen onabotulinumtoxinA Flunarizine Venlafaxine
CGRP inhibitors	Eptinezumab, Galcanezumab, Fremanezumab Erenumab
Opioid (Generic Name)	Acetaminophen and Codeine Butorphanol Tartrate Codeine Cyclobenzaprine Fentanyl Hydrocodone bitartrate and acetaminophen Hydrocodone Bitartrate and Ibuprofen Hydromorphone Hydromorphone Hydrochloride Meperidine Meperidine - promethazine Meperidine-promethazine Morphine Nalbuphine Oxycodone and Acetaminophen Oxycodone and Aspirin Oxycodone Hydrochloride Oxycodone Hydrochloride and Acetaminophen Tramadol Tramadol HCL Tramadol Hydrochloride Tramadol Hydrochloride and Acetaminophen